1. NF-κB
  2. NF-κB
  3. JSH-23


Cat. No.: HY-13982 Purity: 99.48%
Handling Instructions

JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM.

For research use only. We do not sell to patients.

JSH-23 Chemical Structure

JSH-23 Chemical Structure

CAS No. : 749886-87-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 117 In-stock
Estimated Time of Arrival: December 31
5 mg USD 106 In-stock
Estimated Time of Arrival: December 31
10 mg USD 190 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 16 publication(s) in Google Scholar

Top Publications Citing Use of Products

    JSH-23 purchased from MCE. Usage Cited in: PLoS One. 2016 Nov 16;11(11):e0166740.

    HG-induced apoptosis in neonatal rat cardiomyocytes is mediated by activation of the NF-κB pathway. (A-B). Neonatal rat cardiomyocytes are pretreated with 10–20 μM JSH-23 and exposed to HG for 36 h. Levels of caspase-3 and cleaved caspase-3 and Bax/Bcl-2 ratios are determined by western blotting.

    JSH-23 purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2017;10(6):6544-6551.

    JSH-23 is added into MDA-MB-231 cells with the dose of 0 μmol, 1 μmol, 5 μmol when the cell planking density reaches about 60%. Then samples incubated for 24 h are collected when the cell density reaches about 80% and confirmed by western blot.

    JSH-23 purchased from MCE. Usage Cited in: Cancer Lett. 2018 Aug 1;428:77-89.

    Western blots show that the NF-κB inhibitors BAY11-7082, Parthenolide, and JSH-23 cause dramatic time- and dose-dependent reductions in MGMT protein expression in LN18 and T98G glioma cells.

    JSH-23 purchased from MCE. Usage Cited in: Front Pharmacol. 2018 Jun 21;9:660.

    By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (erlotinib), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.

    JSH-23 purchased from MCE. Usage Cited in: J Mol Cell Biol. 2018 Oct 15. 

    Cytoplasmic LPS-induced GSDMB and GSDMD expression are both significantly attenuated by either JSH-23 or QNZ.

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM.

    IC50 & Target[1]


    7.1 μM (IC50, in RAW 264.7 cells)

    In Vitro

    JSH-23 inhibits lipopolysaccharide (LPS)-induced chromatin condensation in a dose-dependent manner, corresponding to 44±4% inhibition at 3 μM, 63±5% at 10 μM and 93±3% at 30 μM[1]. JSH-23 (5, 10, and 15 μM) significantly reduces mean neuronal migration in LPS-activated cells[2]. Co-treatment of A2780 cells with JSH-23 and clinically ineffective transplatin at their IC50 concentrations (130 μM transplatin and 20 μM JSH-23) for 72 h also causes a more pronounced decrease in cell viability compared to the effects of transplatin or JSH-23 alone[3].

    In Vivo

    JSH-23 (1 and 3 mg/kg, p.o.) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic animals and decreases the nerve lipid peroxidation, partially replenishes the depleted levels of GSH in nerve of diabetic rats. JSH-23 inhibits nuclear translocation of p65/p50 subunit in the sciatic nerve and also lowers the elevated IL-6, TNF-α, cyclo-oxygenase (COX-2) and inducible nitric oxide synthase (iNOS) levels/expression[4].

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 56 mg/mL (233.00 mM)

    *"≥" means soluble, but saturation unknown.

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.1608 mL 20.8039 mL 41.6077 mL
    5 mM 0.8322 mL 4.1608 mL 8.3215 mL
    10 mM 0.4161 mL 2.0804 mL 4.1608 mL
    *Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    Apoptosis is analyzed by 4',6-diamidino-2-phenylindole (DAPI) staining. Macrophages RAW 264.7 incubated with JSH-23 are treated with 1 μg/mL LPS and/or sample for 24 h. The cells are stained with 1 μg/mL DAPI for 30 min at 37°C and then analyzed using fluorescence microscopy with excitation at 300-500 nm. Cells with nuclei containing clearly condensed chromatin or cells with fragmented nuclei are scored as an apoptosis index.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    Male Sprague Dawley rats (250-270 g) are used and fed on standard rat diet and water ad libitum. Diabetes is induced by single dose of streptozotocin (STZ, 55 mg/kg, intraperitoneally) in citrate buffer. Blood samples are collected 48 h after STZ administration. Rats with plasma glucose level more than 250 mg/dL are considered as diabetics and are further considered for study. The experimental groups comprised of non-diabetic control rats (ND), diabetic control rats (STZ-D) and diabetic rats treated with two doses of JSH-23 (STZ-D + JSH 1 and STZ-D + JSH 3, respectively, for 1 and 3 mg/kg, orally in 0.5% sodium carboxymethyl cellulose). After 6 weeks of diabetes induction, the drug is administered daily for a period of 2 weeks. The functional, behavioural and biochemical experiments are performed 24 h after the administration of last dose.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.





    Room temperature in continental US; may vary elsewhere

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.:


    Cat. No.: HY-13982